NewAmsterdam Pharma Company NV
NAMS34.300USD
+2.240+6.99%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
3.88BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über NewAmsterdam Pharma Company NV Unternehmen
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
NewAmsterdam Pharma Company NV Informationen
BörsenkürzelNAMS
Name des UnternehmensNewAmsterdam Pharma Company NV
IPO-datumNov 23, 2022
CEODavidson (Michael Harvey)
Anzahl der mitarbeiter68
WertpapierartOrdinary Share
GeschäftsjahresendeNov 23
AddresseGooimeer 2-35
StadtNAARDEN
BörseNASDAQ OMX - NASDAQ BASIC
LandNetherlands
Postleitzahl1411 DC
Telefon31352062971
Websitehttps://ir.newamsterdampharma.com/
BörsenkürzelNAMS
IPO-datumNov 23, 2022
CEODavidson (Michael Harvey)
Führungskräfte von NewAmsterdam Pharma Company NV
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
10.36K
+3400.00%
Mr. John W. Smither
Mr. John W. Smither
Temporary Non-Executive Independent Director
Temporary Non-Executive Independent Director
3.40K
+3400.00%
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
3.40K
+3400.00%
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. John Kastelein
Dr. John Kastelein
Chief Scientific Officer, Non-Executive Director
Chief Scientific Officer, Non-Executive Director
--
--
Ms. Juliette Audet
Ms. Juliette Audet
Chief Business Officer
Chief Business Officer
--
--
Dr. Louis Lange, M.D., Ph.D.
Dr. Louis Lange, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Nicholas Downing, M.D.
Dr. Nicholas Downing, M.D.
Director
Director
--
--
Ms. Janneke Van Der Kamp
Ms. Janneke Van Der Kamp
Temporary Non-Executive Director
Temporary Non-Executive Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
10.36K
+3400.00%
Mr. John W. Smither
Mr. John W. Smither
Temporary Non-Executive Independent Director
Temporary Non-Executive Independent Director
3.40K
+3400.00%
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
3.40K
+3400.00%
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. John Kastelein
Dr. John Kastelein
Chief Scientific Officer, Non-Executive Director
Chief Scientific Officer, Non-Executive Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Wed, Nov 19
Aktualisiert: Wed, Nov 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Frazier Life Sciences Management, L.P.
14.73%
RA Capital Management, LP
8.94%
Capital World Investors
8.66%
Forbion Capital Partners
8.12%
Viking Global Investors LP
5.71%
Andere
53.83%
Aktionäre
Aktionäre
Anteil
Frazier Life Sciences Management, L.P.
14.73%
RA Capital Management, LP
8.94%
Capital World Investors
8.66%
Forbion Capital Partners
8.12%
Viking Global Investors LP
5.71%
Andere
53.83%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
29.12%
Investment Advisor/Hedge Fund
23.40%
Venture Capital
20.18%
Private Equity
14.73%
Hedge Fund
13.05%
Research Firm
2.37%
Family Office
1.70%
Sovereign Wealth Fund
1.00%
Individual Investor
0.56%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
314
117.45M
103.58%
-6.71M
2025Q3
283
121.74M
107.54%
+4.12M
2025Q2
263
127.89M
114.87%
+4.67M
2025Q1
255
126.71M
112.87%
+7.17M
2024Q4
216
108.34M
98.72%
+13.96M
2024Q3
194
82.73M
88.90%
-12.05M
2024Q2
184
81.92M
90.19%
-12.22M
2024Q1
155
81.92M
90.50%
-4.21M
2023Q4
117
72.34M
86.57%
-9.73M
2023Q3
116
71.44M
85.50%
-13.42M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Frazier Life Sciences Management, L.P.
16.70M
14.73%
--
--
Nov 01, 2025
RA Capital Management, LP
10.14M
8.94%
--
--
Sep 30, 2025
Capital World Investors
9.82M
8.66%
+1.43M
+17.11%
Sep 30, 2025
Forbion Capital Partners
9.21M
8.12%
-1.37M
-12.92%
Sep 30, 2025
Viking Global Investors LP
6.48M
5.71%
-503.00K
-7.21%
Sep 30, 2025
Bain Capital Life Sciences Investors, LLC
5.67M
5%
-4.80M
-45.83%
Dec 02, 2025
Fidelity Management & Research Company LLC
5.39M
4.76%
+3.57M
+195.28%
Sep 30, 2025
Deerfield Management Company, L.P.
4.27M
3.76%
-849.26K
-16.60%
Sep 30, 2025
Wellington Management Company, LLP
4.02M
3.55%
+697.13K
+20.98%
Sep 30, 2025
Jennison Associates LLC
4.20M
3.7%
+1.25M
+42.51%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Global X Guru Index ETF
1.82%
ALPS Medical Breakthroughs ETF
1.81%
Virtus LifeSci Biotech Clinical Trials ETF
1.22%
First Trust Small Cap Growth AlphaDEX Fund
1.05%
First Trust NASDAQ Pharmaceuticals ETF
0.83%
Capital Group US Small and Mid Cap ETF
0.68%
ProShares Ultra Nasdaq Biotechnology
0.57%
Invesco Dorsey Wright SmallCap Momentum ETF
0.55%
First Trust Small Cap Core Alphadex Fund
0.43%
Invesco Nasdaq Biotechnology ETF
0.42%
Mehr Anzeigen
Global X Guru Index ETF
Anteil1.82%
ALPS Medical Breakthroughs ETF
Anteil1.81%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil1.22%
First Trust Small Cap Growth AlphaDEX Fund
Anteil1.05%
First Trust NASDAQ Pharmaceuticals ETF
Anteil0.83%
Capital Group US Small and Mid Cap ETF
Anteil0.68%
ProShares Ultra Nasdaq Biotechnology
Anteil0.57%
Invesco Dorsey Wright SmallCap Momentum ETF
Anteil0.55%
First Trust Small Cap Core Alphadex Fund
Anteil0.43%
Invesco Nasdaq Biotechnology ETF
Anteil0.42%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
